Emerging roles for calcium-regulating hormones beyond osteolysis

Trends in Endocrinology and Metabolism

Volumn 21, Issue 8, 2010, Pages 512-518

  Goltzman, David ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; MESSENGER RNA; PARATHYROID HORMONE; VITAMIN D;

GENE DELETION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; MUSCULOSKELETAL FUNCTION; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOCRINE COMMUNICATION; BONE AND BONES; BONE DISEASES; CALCITRIOL; CALCIUM; GROWTH PLATE; HUMANS; METABOLISM, INBORN ERRORS; OSTEOGENESIS; OSTEOLYSIS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN;

EID: 77955274338     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.04.002     Document Type: Review

References (68)

1. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81:239-297.
2. Clines G.A., Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 2005, 12:549-583.
3. Neer R.M., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
4. Clemens T.L., et al. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br. J. Pharmacol. 2001, 134:1113-1136.
5. Bouillon R., et al. Vitamin D and health: perspectives from mice and man. J. Bone Miner. Res. 2008, 23:974-979.
6. Haussler M.R., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66(Suppl. 2):S98-S112.
7. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch. Biochem. Biophys. 2008, 473:218-224.
8. Miao D., et al. Parathyroid hormone is essential for normal fetal bone formation. J. Clin. Invest. 2002, 109:1173-1182.
9. Kronenberg H.M. PTHrP and skeletal development. Ann. N. Y. Acad. Sci. 2006, 1068:1-13.
10. Maeda Y., et al. Indian Hedgehog produced by postnatal chondrocytes is essential for maintaining a growth plate and trabecular bone. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6382-6387.
11. Datta N.S., Abou-Samra A.B. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009, 21:1245-1254.
12. Dean T., et al. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol. Endocrinol. 2008, 22:156-166.
13. Fiaschi-Taesch N.M., Stewart A.F. parathyroid hormone-related protein as an intracrine factor - trafficking mechanisms and functional consequences. Endocrinology. 2003, 144:407-411.
14. Lam M.H., et al. Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules. Mol. Endocrinol. 2002, 16:390-401.
15. Fiaschi-Taesch N., et al. Parathyroid-hormone-related protein as a regulator of pRb and the cell cycle in arterial smooth muscle. Circulation 2004, 110:177-185.
16. Watson P.H., et al. Nuclear localization of the type 1 PTH/PTHrP receptor in rat tissues. J. Bone Miner. Res. 2000, 15:1033-1044.
17. Miao D., et al. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20309-20314.
18. Toribio, R.E. et al. (2010) The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J. [Epub ahead of print] PMID: 20145205 [PubMed].
19. Rodriguez-Enfedaque A., et al. FGF1 nuclear translocation is required for both its neurotrophic activity and its p53-dependent apoptosis protection. Biochim. Biophys. Acta 2009, 1793:1719-1727.
20. Meunier S., et al. Pivotal role of translokin/CEP57 in the unconventional secretion versus nuclear translocation of FGF2. Traffic 2009, 10:1765-1772.
21. Kosman J., et al. Translocation of fibroblast growth factor-10 and its receptor into nuclei of human urothelial cells. J. Cell. Biochem. 2007, 102:769-785.
22. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol. Metab. 2010, 21:59-67.
23. Lee M., Partridge N.C. Parathyroid hormone signaling in bone and kidney. Curr. Opin. Nephrol. Hypertens. 2009, 18:298-302.
24. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
25. Bellido T., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
26. van Bezooijen R.L., et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005, 16:319-327.
27. Li X., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280:17815-17822.
28. Kramer I., et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res. 2009, [Epub ahead of print] PMID: 19594304 [PubMed].
29. Sims N.A. Building bone with a SOST-PTH partnership. J. Bone Miner. Res. 2010, 25:175-177.
30. Kramer I., et al. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol. Metab. 2010, 21:237-244.
31. Richard C., et al. The calcium sensing receptor and 25-hydroxyvitamin D-1alpha-hydroxylase interact to modulate skeletal growth and bone turnover. J. Bone Miner. Res. 2010, [Epub ahead of print] PMID: 20200973 [PubMed]. 10.1002/jbmr.58.
32. Miao D., et al. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 2004, 145:2046-2053.
33. Xue Y., et al. Exogenous PTH-related protein and PTH improve mineral and skeletal status in 25-hydroxyvitamin D-1alpha-hydroxylase and PTH double knockout mice. J. Bone Miner. Res. 2005, 20:1766-1777.
34. Horwitz M.J., et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab. 2010, 95:1279-1287.
35. Ahlstrom M., et al. Extracellular calcium regulates parathyroid hormone-related peptide expression in osteoblasts and osteoblast progenitor cells. Bone 2008, 42:483-490.
36. Mak K.K., et al. Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev. Cell 2008, 14:674-688.
37. Zhao Q., et al. Expression of parathyroid hormone-related peptide (PthrP) and its receptor (PTH1R) during the histogenesis of cartilage and bone in the chicken mandibular process. J. Anat. 2002, 201:137-145.
38. Chen X., et al. Initial characterization of PTH-related protein gene-driven lacZ expression in the mouse. J. Bone Miner. Res. 2006, 21:113-123.
39. Miao D., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 2005, 115:2402-2411.
40. Kim C.J., et al. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 2007, 92:3177-3182.
41. Liberman U.A. Vitamin D-resistant diseases. J. Bone Miner. Res. 2007, 22(Suppl. 2):V105-107.
42. Goltzman D., et al. Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J. Steroid Biochem. Mol. Biol. 2004, 89-90:485-489.
43. Demay M.B. Mechanism of vitamin D receptor action. Ann. N. Y. Acad. Sci. 2006, 1068:204-213.
44. Panda D.K., et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 2004, 279:16754-16766.
45. Xue Y., et al. Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum. Mol. Genet. 2005, 14:1515-1528.
46. Xue Y., et al. Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles. Endocrinology 2006, 147:4801-4810.
47. Samadfam R., et al. Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone. J. Bone Miner. Res. 2008, 23:1257-1266.
48. Gardiner E.M., et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 2000, 14:1908-1916.
49. Sato M., et al. A non-secosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia. J. Bone Miner. Res. 2010, [Epub ahead of print] PMID: 20200930 [PubMed]. 10.1002/jbmr.15.
50. Teng M., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
51. Autier P., et al. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 2007, 167:1730-1737.
52. Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 2009, 94:26-34.
53. Baeke F., et al. Vitamin D insufficiency: implications for the immune system. Pediatr. Nephrol. 2010, [Epub ahead of print] PMID: 20180136 [PubMed]. 10.1007/s00467-010-1452-y.
54. Zinser G.M., et al. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 2005, 97:153-164.
55. Zeitz U., et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17:509-511.
56. Li Y.C., et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
57. Zhou C., et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008, 74:170-179.
58. Hewison M., et al. Extra-renal 1α-hydroxylase activity and human disease. Vitamin D 2005, 1379-1402. Elsevier Academic Press. 2nd edn. D. Feldman (Ed.).
59. Vanhooke J.L., et al. CYP27B1 null mice with lacZ reporter gene display no 25-hydroxyvitamin D3-1alpha-hydroxylase promoter activity in the skin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:75-80.
60. Tsutsui T.W., et al. Development of craniofacial structures in transgenic mice with constitutively active PTH/PTHrP receptor. Bone 2008, 42:321-331.
61. Thomson M., et al. Parathyroid hormone-related peptide modulates signal pathways in skin and hair follicle cells. Exp. Dermatol. 2003, 12:389-395.
62. Hens J.R., Wysolmerski J.J. Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Res. 2005, 7:220-224.
63. Mitchell D.M., Jüppner H. Regulation of calcium homeostasis and bone metabolism in the fetus and neonate. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:25-30.
64. Escande B., et al. Developmental aspects of parathyroid hormone-related protein biology. Semin. Perinatol. 2001, 25:76-84.
65. Fritsch S., et al. Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J. Am. Soc. Nephrol. 2004, 15:2588-2600.
66. Esbrit P., et al. Parathyroid hormone-related protein as a renal regulating factor. From vessels to glomeruli and tubular epithelium. Am. J. Nephrol. 2001, 21:179-184.
67. Rehan V.K., Torday J.S. Exploiting the PTHrP signaling pathway to treat chronic lung disease. Drugs Today (Barc). 2007, 43:317-331.
68. Legakis I. The role of parathyroid hormone-related protein (PTHrP) in the pathophysiology of diabetes mellitus. Mini Rev. Med. Chem. 2009, 9:717-723.